Blood Cancer United

What it reported doing in 2024

A) research programs: at blood cancer united, we are pushing boundaries toward powerful new therapies. We propel groundbreaking cancer treatments through all phases of the research and drug development process and are proud that our support has been key to advancing 80% of the 153 blood cancer treatment approvals since 2017.as we continued to support the search for lifesaving and less toxic treatments in 2025, we invested in exciting research frontiers, including precision medicine, immunotherapy, and links between mutations and blood cancer-advancements that are changing the paradigm of cancer treatment. In the process, we propelled several novel science initiatives to new heights-many of which hardly seemed possible just a short time ago.with advisory input from recognized biomedical research experts, blood cancer united funded exemplary projects across the entire research continuum relevant to improve outcomes for blood cancer patients, from basic laboratory science through clinical trials, and from investigator-initiated research to private-sector drug development alliances. Blood cancer united is deliberate and purposeful in finding and supporting research that is most likely to help patients as soon as possible. In addition, while blood cancer united dedicates substantial funding to advancing novel treatments for blood cancer, we recognize that it is equally important that we commit to improving patient access to these essential therapies. To this end, blood cancer united also supports health services research working to identify barriers that prevent certain patients from being able to access the treatment and care that they need and finding actionable solutions that blood cancer united can implement to overcome these barriers and advance its mission. To date, blood cancer united has invested over $2 billion in research aimed at helping all blood cancer patients live better, longer lives. Our sustained research investment over multiple decades has paid off handsomely. This is best demonstrated by our seminal investment in chimeric antigen receptor t-cell (car t) therapy starting in 1990 that, since 2017, has translated into 18 fda-approvals for pediatric and adult b-cell acute leukemia, for several types of non-hodgkin lymphoma, and multiple myeloma. Car t-cell therapy has in some cases produced cures in patients who have failed all other therapeutic options.in fiscal year 2025, blood cancer united supported research in the u.s., canada and several other countries with a total research disbursement of approximately $81.3 million. Research funding was distributed across all blood cancers.equity in access research program in fiscal year 2022, blood cancer united launched the equity in access research program, which aims to fund health services research that will generate actionable evidence to assist blood cancer united in advocating for changes in healthcare policy, developing patient-facing programs, and fostering practice change to extend and improve the lives of all blood cancer patients. Equity in access has awarded nearly $18 million to researchers addressing critical issues such as the cost of oral anticancer medications, the role of health insurance in financial hardship, and access for every patient to clinical trials. Blood cancer united recognizes the critical need for high-quality evidence on interventions to increase participation in therapeutic cancer clinical trials, which are considered high-quality cancer care, particularly among underrepresented groups (e.g., people who have low incomes, people who live in rural areas, ethnically and racially minoritized groups). In fiscal year 2025 alone, equity in access awarded nearly $5 million to researchers who will implement and evaluate novel intervention approaches designed to increase therapeutic clinical trial enrollment. Therapy acceleration program (tap)tap is blood cancer united's mission-driven, strategic venture philanthropy initiative that seeks to accel

Financial Efficiency

• Mission deployment rate: 84.1%; rating input score 84
• Program expense ratio: 74.3%; rating input score 74
• Fundraising efficiency: $6.34 raised per $1 spent on fundraising; rating input score 28; 28th percentile among comparable filings

Transparency & Controls

• Consistency checks: 90%; rating input score 90; 4th percentile among comparable filings
• Pay-setting controls: 5 of 6 controls in place; rating input score 83
  • Compensation committee: Pass
  • Independent consultant: Pass
  • Other Form 990s reviewed: Pass
  • Written employment contract: Missing
  • Compensation survey or study: Pass
  • Board or committee approval: Pass
• Foreign activity oversight: 3 of 8 controls in place; rating input score 38
  • Claims monitoring procedures: Pass
  • Requires narrative reports: Pass
  • Conducts field audits: Limited
  • May suspend future funding: Limited
  • Requires financial reports: Pass
  • Conducts site visits: Limited
  • Requires grant agreements: Limited
  • May require repayment: Limited
• Grant itemization coverage: 100%; rating input score 100; 77th percentile among comparable filings
• Major donor itemization: Yes; rating input score 100
• Related-party transparency: Limited

Accountability

• Independent voting board: 82.6%; rating input score 83; 30th percentile among comparable filings
• Governance controls: 9 of 9 controls in place; rating input score 100
  • Conflict-of-interest policy: Pass
  • Whistleblower policy: Pass
  • Document-retention policy: Pass
  • CEO compensation review process: Pass
  • Other executive compensation review process: Pass
  • Form 990 shared with the board: Pass
  • Board meeting minutes documented: Pass
  • Audit committee oversight: Pass
  • Independent financial-statement audit: Pass

Sustainability

• Operating margin: -11%; rating input score 7; 7th percentile among comparable filings
• Total-asset coverage ratio: 1.34; rating input score 49; 49th percentile among comparable filings
• Liabilities to assets ratio: 0.32; rating input score 53; 53rd percentile among comparable filings
• Officer compensation ratio: 1.7%; rating input score 62; 62nd percentile among comparable filings

Growth

• Program expense growth: 3.4% per year; rating input score 100; 25th percentile among comparable filings
• Revenue growth: 3.2% per year; rating input score 100; 24th percentile among comparable filings
• Asset growth: 8.9% per year; rating input score 100; 64th percentile among comparable filings